BRCA1 and breast cancer: This has been shown by a recent study which found significantly longer survival free of invasive or distant disease when using olaparib as adjuvant therapy after neoadjuvant or adjuvant chemotherapy and local therapy in early breast cancer patients with BRCA1 or BRCA2 germline pathogenic variant [53].